A Double Blind, Placebo Controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the IKK Inhibitor, SAR113945, Following Intra-articular Administration in Patients With Knee Osteoarthritis .

Trial Profile

A Double Blind, Placebo Controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the IKK Inhibitor, SAR113945, Following Intra-articular Administration in Patients With Knee Osteoarthritis .

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2010

At a glance

  • Drugs SAR 113945 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Dec 2010 Planned End Date changed from 1 Jan 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 07 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 May 2010 Planned end date changed from 1 Nov 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top